Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement levels. The company most associated with obesity treatments, Denmark-based Novo Nordisk (NYSE: NVO),

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated and prescribed. Glass points out that obesity is a complex condition, and people with obesity often have other health issues as well, related to the heart, kidney, and liver. “It’s not just about weight,” he says.

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes drugs from compounding pharmacies.

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and diabetes drugs Zepbound and Mounjaro off a list of medicines in short supply,

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.